Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Kroschinsky F, et al. Among authors: quinson am. Invest New Drugs. 2020 Oct;38(5):1472-1482. doi: 10.1007/s10637-020-00916-3. Epub 2020 Mar 14. Invest New Drugs. 2020. PMID: 32172489 Free PMC article. Clinical Trial.
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Kroschinsky F, et al. Among authors: quinson am. Invest New Drugs. 2021 Feb;39(1):283-284. doi: 10.1007/s10637-020-00949-8. Invest New Drugs. 2021. PMID: 32474843 Free PMC article. No abstract available.
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Kroschinsky F, et al. Among authors: quinson am. Invest New Drugs. 2021 Feb;39(1):285-286. doi: 10.1007/s10637-020-00964-9. Invest New Drugs. 2021. PMID: 32578153 Free PMC article. No abstract available.
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.
Balzarotti M, Magagnoli M, Canales MÁ, Corradini P, Grande C, Sancho JM, Zaja F, Quinson AM, Belsack V, Maier D, Carlo-Stella C. Balzarotti M, et al. Among authors: quinson am. Invest New Drugs. 2021 Aug;39(4):1028-1035. doi: 10.1007/s10637-020-01054-6. Epub 2021 Feb 1. Invest New Drugs. 2021. PMID: 33523334 Free PMC article. Clinical Trial.
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Danilov AV, Spurgeon SE, Siddiqi T, Quinson AM, Maier D, Smith D, Brown JR. Danilov AV, et al. Among authors: quinson am. Invest New Drugs. 2021 Aug;39(4):1099-1105. doi: 10.1007/s10637-020-01056-4. Epub 2021 Mar 8. Invest New Drugs. 2021. PMID: 33683501 Free PMC article. Clinical Trial.
Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.
Giaquinto C, Anabwani G, Feiterna-Sperling C, Nuttall J, Mompati K, Königs C, Mensa FJ, Sabo JP, Yong CL, MacGregor TR, Nguyen T, Quinson AM. Giaquinto C, et al. Among authors: quinson am. Pediatr Infect Dis J. 2014 Jul;33(7):e173-9. doi: 10.1097/INF.0000000000000241. Pediatr Infect Dis J. 2014. PMID: 24378938 Clinical Trial.
Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.
Yong CL, Gathe JC, Knecht G, Orrell C, Mallolas J, Podzamczer D, Trottier B, Zhang W, Sabo JP, Vinisko R, Drulak M, Quinson AM. Yong CL, et al. Among authors: quinson am. HIV Clin Trials. 2017 Nov-Dec;18(5-6):189-195. doi: 10.1080/15284336.2017.1386811. HIV Clin Trials. 2017. PMID: 29210627 Clinical Trial.
22 results